- Home
- FSP vs CNTX Comparison
FSP vs CNTX Comparison
Compare FSP & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FSP | CNTX |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 47.7M |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FSP | CNTX |
|---|---|---|
| Price | $0.40 | $0.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 406.8K | ★ 2.2M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | 15.69 | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,162,000.00 | N/A |
| Revenue This Year | $17.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $0.35 |
| 52 Week High | $1.73 | $3.62 |
Technical Indicators
Market Signals| Indicator | FSP | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.37 | 28.21 |
| Support Level | N/A | N/A |
| Resistance Level | $0.51 | $0.70 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 4.92 | 8.31 |
Price Performance
Historical ComparisonAbout FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.